Celgene's Multiple Myeloma Triplet Succeeds in Key Phase III Trial Post author:Sam Post published:February 5, 2018 Post category:BioPharma The international clinical study, OPTIMISMM, achieved its primary endpoint. Source: BioSpace You Might Also Like Array BioPharma Touts Phase III Results for Melanoma Therapy March 21, 2018 Johns Hopkins Gets a $65M Boost to Take Promising Drugs Into Clinic November 15, 2017 On a Roll: FDA OKs Genentech's Gazyva for Untreated Follicular Lymphoma November 16, 2017
